RUNX1: an emerging therapeutic target for cardiovascular disease | Zendy

Alexandra Riddell | Zendy; Martin McBride | Zendy; Thomas Braun | Zendy; Stuart A. Nicklin | Zendy; Ewan R. Cameron | Zendy; Christopher M. Loughrey | Zendy; Tamara P. Martin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

RUNX1: an emerging therapeutic target for cardiovascular disease

Author(s) -

Alexandra Riddell,

Martin McBride,

Thomas Braun,

Stuart A. Nicklin,

Ewan R. Cameron,

Christopher M. Loughrey,

Tamara P. Martin

Publication year - 2020

Publication title -

cardiovascular research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.774

H-Index - 219

eISSN - 1755-3245

pISSN - 0008-6363

DOI - 10.1093/cvr/cvaa034

Subject(s) - runx1 , transcription factor , regulator , heart failure , myocardial infarction , medicine , biology , cancer research , immunology , bioinformatics , genetics , gene

Runt-related transcription factor-1 (RUNX1), also known as acute myeloid leukaemia 1 protein (AML1), is a member of the core-binding factor family of transcription factors which modulate cell proliferation, differentiation, and survival in multiple systems. It is a master-regulator transcription factor, which has been implicated in diverse signalling pathways and cellular mechanisms during normal development and disease. RUNX1 is best characterized for its indispensable role for definitive haematopoiesis and its involvement in haematological malignancies. However, more recently RUNX1 has been identified as a key regulator of adverse cardiac remodelling following myocardial infarction. This review discusses the role RUNX1 plays in the heart and highlights its therapeutic potential as a target to limit the progression of adverse cardiac remodelling and heart failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research